BIONTECH

We aim to bring novel oncology and infectious disease therapies to the market. BioNTech is also exploring how to apply its technology to advancements in treating allergies, inflammatory diseases, and regenerative medicine... BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine. We are also continuously evaluating ways to democratize the access to healthcare in the long-term... We are developing a range of novel cell therapies in which the patient's T cells are modified to target cancer-specific antigens. These include two platforms for the treatment of solid tumors: chimeric antigen receptor (CAR T) cells and T cell receptor (TCR) programs. We are also combining our cell therapy programs with a supercharging technology based on our mRNA FixVac platform to..

Also known as: BioNTech Australia, BioNTech Delivery Technologies GmbH, BioNTech Rwanda Ltd., BioNTech SE, BioNTech Service Center, BioNTech Small Molecules GmbH, BioNTech Turkey, BioNTech US

Registration numbers: RB 48720 (W)

VAT numbers: DE 263 382 495

Primary location: Mainz Germany